O
VSTM icon

OrbiMed’s Verastem VSTM Stock Holding History

OrbiMed’s Portfolio VSTM Stock Details VSTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-887,561
Closed -$7.84M – 129
2025
Q3 		$7.84M Buy
+887,561
New +$6.61M 0.18% 78
2025
Q2 		– Sell
-2,862,448
Closed -$17.3M – 122
2025
Q1 		$17.3M Hold
2,862,448
– – 0.41% 47
2024
Q4 		$14.8M Hold
2,862,448
– – 0.3% 62
2024
Q3 		$8.56M Buy
2,862,448
+1,333,333
+87% +$3.62M 0.16% 81
2024
Q2 		$4.56M Hold
1,529,115
– – 0.09% 93
2024
Q1 		$18M Hold
1,529,115
– – 0.33% 69
2023
Q4 		$12.4M Hold
1,529,115
– – 0.25% 72
2023
Q3 		$12.4M Hold
1,529,115
– – 0.26% 74
2023
Q2 		$11.4M Buy
1,529,115
+153,845
+11% +$1.07M 0.21% 83
2023
Q1 		$6.85M Hold
1,375,270
– – 0.13% 95
2022
Q4 		$6.64M Sell
1,375,270
-58,063
-4% -$285K 0.13% 85
2022
Q3 		$14.6K Buy
+1,433,333
New +$20M 0.27% 76

Other funds holding VSTM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

OrbiMed's VSTM Position: Q4 2025 in Review

OrbiMed sold out of Verastem (VSTM) in Q4 2025, closing a stake of 887,561 shares — an estimated $7.84M sold.

OrbiMed first reported a position in VSTM in Q3 2022 and held it in 12 quarters. The position peaked at $18M in Q1 2024. 142 funds tracked by Wall St. Rank hold VSTM as of Q4 2025.

  • OrbiMed reported no remaining Verastem position as of Q4 2025 after selling out during the quarter.
  • OrbiMed sold 887,561 Verastem shares in Q4 2025, an estimated $7.84M.
  • OrbiMed first reported a position in Verastem in Q3 2022 and held it in 12 quarters.
  • OrbiMed's Verastem position peaked at $18M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Verastem as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.